Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nrx Pharmaceuticals Inc (NRXP)

Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,419
  • Shares Outstanding, K 33,068
  • Annual Sales, $ 1,225 K
  • Annual Income, $ -25,130 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 1.97
  • Price/Sales 64.25
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 173.42% (+3.75%)
  • Historical Volatility 90.53%
  • IV Percentile 32%
  • IV Rank 21.90%
  • IV High 734.57% on 02/13/26
  • IV Low 16.06% on 09/08/25
  • Expected Move (DTE 19) 0.55 (25.23%)
  • Put/Call Vol Ratio 1.26
  • Today's Volume 43
  • Volume Avg (30-Day) 344
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 4,734
  • Open Int (30-Day) 6,942
  • Expected Range 1.64 to 2.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.00
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate -0.02
  • Prior Year -0.34
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.62 +35.19%
on 03/09/26
2.49 -12.05%
on 03/25/26
+0.33 (+17.74%)
since 02/27/26
3-Month
1.62 +35.19%
on 03/09/26
2.77 -20.80%
on 01/02/26
-0.37 (-14.45%)
since 12/26/25
52-Week
1.58 +38.61%
on 04/07/25
3.84 -42.97%
on 10/07/25
+0.12 (+5.80%)
since 03/27/25

Most Recent Stories

More News
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)

The show also broadcasts across MENA and Latin America as sponsored programming.

TRN : 31.19 (-0.89%)
PETV : 0.7352 (-1.34%)
SNYR : 1.2099 (+2.53%)
ACXP : 3.76 (-6.23%)
IGC : 0.2553 (-1.96%)
VTIX : 6.68 (+2.45%)
LTRN : 1.1200 (-46.41%)
NRXP : 2.19 (-7.98%)
YYGH : 1.0300 (+0.49%)
DVLT : 0.5693 (-6.53%)
VVOS : 1.1500 (-3.36%)
NRx Pharmaceuticals (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress

NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including...

NRXP : 2.19 (-7.98%)
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing...

NRXP : 2.19 (-7.98%)
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST

Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant

CAST : 3.98 (-11.16%)
RDZN : 1.0700 (-6.96%)
SDST : 2.38 (+2.59%)
LTRN : 1.1200 (-46.41%)
VRTX : 433.07 (-4.56%)
NRXP : 2.19 (-7.98%)
DVLT : 0.5693 (-6.53%)
SGTM : 0.2178 (+8.90%)
CISO : 0.3290 (-5.08%)
NRx Pharmaceuticals (NASDAQ: NRXP) Schedules March 24 Conference Call To Review 2025 Results, Clinical Progress

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will host a conference call at 8:00 a.m. ET on March 24, 2026, to review financial results for the fiscal year...

NRXP : 2.19 (-7.98%)
BMWYY : 29.2000 (+4.58%)
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced...

NRXP : 2.19 (-7.98%)
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product

NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a letter from the FDA’s Bioequivalence Program stating no bioequivalence deficiencies were identified at this time in its Abbreviated New...

NRXP : 2.19 (-7.98%)
BMWYY : 29.2000 (+4.58%)
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application

Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA). FDA has advised NRx in written correspondence that it has not identified...

NRXP : 2.19 (-7.98%)
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Guidance Supporting NDA Review For NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced that minutes from a Type C meeting with the U.S. Food and Drug Administration support the agency’s willingness to review a New Drug Application for NRX-100,...

NRXP : 2.19 (-7.98%)
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research....

NRXP : 2.19 (-7.98%)

Business Summary

NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 2.47
2nd Resistance Point 2.39
1st Resistance Point 2.29
Last Price 2.19
1st Support Level 2.12
2nd Support Level 2.04
3rd Support Level 1.94

See More

52-Week High 3.84
Fibonacci 61.8% 2.98
Fibonacci 50% 2.71
Fibonacci 38.2% 2.44
Last Price 2.19
52-Week Low 1.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.